NFE2L2 and non-small cell lung carcinoma: Activating mutations in NRF2/KEAP1 are found in approximately a third of non-small cell lung cancer (NSCLC) patients13,14, with NRF2 activation associated with a worse prognosis in patients treated with first-line therapy3,15.